Iminosugars and methods of treating viral diseases
Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.
1. A method of inhibiting production of infectious Dengue virus particles in a human with a Dengue viral infection comprising administering to a human subject in need thereof an effective amount of N-(9-Methoxynonyl)deoxynojirimycin or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the administering comprises administering N-(9-Methoxynonyl)deoxynojirimycin.
3. The method of claim 1 , wherein the administering comprises administering a pharmaceutically acceptable salt of N-(9-Methoxynonyl)deoxynojirimycin.
4. The method of claim 1 , wherein the Dengue viral infection is caused by or associated with a Dengue 1 virus.
5. The method of claim 1 , wherein the Dengue viral infection is caused by or associated with a Dengue 2 virus.
6. The method of claim 1 , wherein the Dengue viral infection is caused by or associated with a Dengue 3 virus.
7. The method of claim 1 , wherein the Dengue viral infection is caused by or associated with a Dengue 4 virus.
8. The method of claim 1 , wherein the N-(9-Methoxynonyl)deoxynojirimycin or the pharmaceutically acceptable salt thereof is administered parenterally.
9. The method of claim 1 , wherein the N-(9-Methoxynonyl)deoxynojirimycin or the pharmaceutically acceptable salt thereof is administered orally.
10. A method of treating a Dengue viral infection comprising administering orally or parenterally to a human subject in need thereof an effective amount of N-(9-Methoxynonyl)deoxynojirimycin or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the N-(9-Methoxynonyl)deoxynojirimycin or the pharmaceutically acceptable salt thereof is administered parenterally.
12. The method of claim 10 , wherein the N-(9-Methoxynonyl)deoxynojirimycin or the pharmaceutically acceptable salt thereof is administered orally.
13. The method of claim 10 , wherein the Dengue viral infection is caused by or associated with a Dengue 2 virus.
14. The method of claim 10 , wherein the administering comprises administering N-(9-Methoxynonyl)deoxynojirimycin.
15. The method of claim 10 , wherein the administering comprises administering a pharmaceutically acceptable salt of N-(9-Methoxynonyl)deoxynojirimycin.
16. A method of reducing or ameliorating the symptoms of a Dengue viral infection comprising administering orally or parenterally to a human subject in need thereof an effective amount of N-(9-Methoxynonyl)deoxynojirimycin or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 , wherein the administering comprises administering N-(9-Methoxynonyl)deoxynojirimycin.
18. The method of claim 16 , wherein the administering comprises administering a pharmaceutically acceptable salt of N-(9-Methoxynonyl)deoxynojirimycin.
19. The method of claim 16 , wherein the N-(9-Methoxynonyl)deoxynojirimycin or the pharmaceutically acceptable salt thereof is administered parenterally.
20. The method of claim 16 , wherein the N-(9-Methoxynonyl)deoxynojirimycin or the pharmaceutically acceptable salt thereof is administered orally.
21. The method of claim 16 , wherein the Dengue viral infection is caused by or associated with a Dengue 2 virus.